Advertisement Bristol-Myers Squibb expands manufacturing agreement with Lonza - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

Bristol-Myers Squibb expands manufacturing agreement with Lonza

Bristol-Myers Squibb (BMS) has expanded its existing multi-year biologics manufacturing agreement with Swiss chemicals and biotechnology firm Lonza.

Bristol Myers Squibb Pharmaceutical Research Institute

The contract expansion will include the production of commercial quantities of a second BMS biologic medicine at Lonza’s mammalian manufacturing facility in Portsmouth, New Hampshire.

Biologic medicines that treat serious diseases are an integral part of BMS’ specialty care portfolio and R&D pipeline.

The companies have collaborated in 2003 to produce commercial supplies of a biologics medicine marketed by BMS across the world.

At present, Lonza also manufactures clinical supplies of an investigational biologics medicine for BMS.

The Swiss firm’s development and manufacturing facilities provide proven expression systems and established platform processes for streamlined scale-up throughout the clinical pipeline.

Bristol-Myers Squibb Global Manufacturing & Supply president Lou Schmukler said: "Our expanded relationship with Lonza is an important example of our global manufacturing strategy to meet anticipated demand for our commercial biologics portfolio and prepare to bring our late-stage clinical assets to patients by supplementing our in-house manufacturing capabilities."

In addition to its Portsmouth facility, Lonza offers three additional clinical-to-commercial mammalian production facilities in Tuas, Singapore; Porrino, Spain; and Slough, UK.

Lonza COO of Pharma & Biotech Segment Marc Funk said: "We are pleased to extend our relationship with Bristol-Myers Squibb for the commercial production of their innovative drug substance.

"This reinforces Lonza’s mission to support life-saving medicines by being a reliable supplier of drug substance for our customers with high-quality commercial GMP manufacturing services delivered to the market."


Image: BMS Pharmaceutical Pharmaceutical Research Institute on Reeds Lane, Moreton which is responsible for the discovery and development of new medicines. Photo: courtesy of Sue Adair